Connect

Partner News

Partner News

DHHS Funding Opportunities

FUNDING OPPORTUNITIES from the Department of Health and Human Services (DHHS)     

________________________________________________________

Department of Health and Human Services – Centers for Disease Control and Prevention – ERA – Epidemiologic Cohort Study of Interstitial Cystitis

Proposal Due Date: January 14, 2020

Expected Number of Awards: 1

Estimated Total Program Funding: $2,490,000

Award Ceiling: $900,000

Award Floor:

Funding Opportunity Number: RFA-DP-21-002 

Purpose: The primary purpose of this funding opportunity is to follow a well-defined cohort of participants with interstitial cystitis (IC) in order to obtain incidence estimates of IC, define the demographic and clinical patterns of IC, and document its longitudinal impact on the health of affected people over time. In addition, the focus of this Notice of Funding Opportunity (NOFO) will include translating the scientific knowledge on IC, extracted from this and prior studies, to support public health practice, including: (1) patient strategies for improving quality of life, (2) provider and patient awareness and education, and (3) medical and self-management of IC. This funding opportunity should be used to help strengthen clinical, community, and public health linkages; and target groups disproportionately impacted by IC.

View more details on this opportunity.

___________________________________________________________

Department of Health and Human Services – Centers for Disease Control and Prevention – ERA – Strengthening Public Health Research and Implementation Science (Operations Research) to Control and Eliminate Infectious Diseases Globally

Effective Date: February 22, 2021

Expected Number of Awards: 6

Estimated Total Program Funding: $60,000,0000

Award Ceiling: $2,000,000

Award Floor:

Funding Opportunity Number: RFA-GH-21-006

Purpose: The purpose of this notice of funding opportunity is to:

View more details on this opportunity.

___________________________________________________________

Department of Health and Human Services – National Institutes of Health – NIAAA Resource-Related Research Projects (R24 Clinical Trial Not Allowed)

Letter of Intent Due Date: 30 days prior to application due date

Proposal Due Date: January 25, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-072

Purpose: The purpose of the Resource-Related Research Projects (R24) grant is to support investigator-initiated resources designed to provide materials and services to support and advance biomedical research on a national basis. An R24 resource grant mechanism is a non-hypothesis-driven activity to provide data, materials, tools, or services that are essential to making timely, high quality, and cost-efficient progress in a field.  Hypothesis-driven research proposals should not be submitted in response to this program announcement but to another mechanism that encourages this type of research.  The resource should be available to any qualified investigator, and should be highly quality controlled, and not duplicate resources available commercially or through other sources.  Resources should be designed to provide services to the broad alcohol research community and should not be limited by any specific regional focus.

View more details on this opportunity.

___________________________________________________________

Department of Health and Human Services – National Institutes of Health – Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)

Letter of Intent Due Date: 30 days prior to application due date

Proposal Due Date: February 5, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-035

Purpose: Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA. This FOA does not and will not support clinical trials for studies of cancer diagnosis and/or oncologic therapy in patients. The proposed investigator-initiated projects should be related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences.

View more details on this opportunity.

___________________________________________________________

Department of Health and Human Services – National Institutes of Health – National Cancer Institute’s Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)

Letter of Intent Due Date: 30 days prior to application due date

Proposal Due Date: February 5, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-033

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to seek research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of the National Cancer Institute’s (NCI) Division of Cancer Treatment and Diagnosis (DCTD). Applicants are strongly encouraged to consult the NCI DCTD website at https://dctd.cancer.gov/ to learn more about the various program goals, research priorities, and strategies developed to fight cancer. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA. Applications that propose phase III clinical trials in any area of cancer research are not sought by and will not be supported through this FOA.

View more details on this opportunity.

___________________________________________________________

Department of Health and Human Services – National Institutes of Health – Exploring the Scientific Value of Existing or New Sepsis Human Biospecimen Collections (R21/R33 – Clinical Trial Not Allowed)

Proposal Due Date: February 16, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-077

Purpose: The purpose of this funding opportunity announcement (FOA) is to support efficient collection, banking, and sharing of biospecimens and associated clinical data from critically ill patients, ultimately for use in mechanistic research on sepsis. The goals of this FOA are to determine the scientific value of existing or newly collected sepsis human biospecimen sets as testbeds for studies on human sepsis and to provide guidance on the best practices for collecting, utilizing, and analyzing human biospecimens, thus maximizing their value for the entire sepsis research community.

View more details on this opportunity.

___________________________________________________________

Department of Health and Human Services – National Institutes of Health – Service-Ready Tools for Identification, Prevention, and Treatment of Individuals at Risk for Suicide (R01 Clinical Trial Optional)

Letter of Intent Due Date: 30 days prior to application due date

Proposal Due Date: February 18, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: RFA-MH-21-110

Purpose: NIMH seeks applications for research projects to evaluate the effectiveness of service-ready tools and technologies that can be used to advance training, quality monitoring, and quality improvement efforts and ultimately improve the availability of evidence-based suicide prevention services. Specifically, this initiative encourages research on the effectiveness-implementation continuum aimed at (1) developing and testing the effectiveness of optimized, service-ready suicide prevention tools for identification, prevention, and treatment of individuals at risk for suicide; and (2) testing strategies to improve adoption, implementation fidelity, and sustained use of these tools, guided by an implementation science framework. Given the focus on practice-ready accessible resources and products that could be readily integrated into practice, NIMH encourages the use of technology and other design features that make the tools scalable and robust against implementation drift, and a deployment-focused approach that takes into account the perspectives of key stakeholders (e.g., service users, providers, administrators) and system-level factors, such as workforce capacity that influence potential integration of tools into clinical workflows.

This Funding Opportunity Announcement (FOA) is intended to support effectiveness research of service-ready tools and technologies for suicide prevention that are statistically powered to provide a definitive answer regarding the study tool’s effectiveness. Support for pilot effectiveness research to evaluate the initial feasibility, tolerability, acceptability, safety, and preliminary indications of effectiveness of service-ready tools and technologies for suicide prevention is provided via the R34 in RFA-MH-21-111. Support for SBIR studies focused on service-ready tools and technologies or suicide prevention is provided via the R43/R44 in RFA-MH-21-112.

View more details on this opportunity.

___________________________________________________________

Department of Health and Human Services – National Institutes of Health – Service-Ready Tools for Identification, Prevention, and Treatment of Individuals at Risk for Suicide (R34 Clinical Trial Optional)

Letter of Intent Due Date: 30 days prior to application due date

Proposal Due Date: February 18, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: RFA-MH-21-111

Purpose: NIMH seeks applications for pilot effectiveness projects to evaluate the preliminary effectiveness of service-ready tools and technologies that can be used to advance training, quality monitoring, and quality improvement efforts and ultimately improve the availability of evidence-based suicide prevention services. Specifically, this initiative encourages research on the effectiveness-implementation continuum aimed at (1) developing and testing the effectiveness of optimized, service-ready suicide prevention tools for identification, prevention, and treatment of individuals at risk for suicide; and (2) testing strategies to improve adoption, implementation fidelity, and sustained use of these tools, guided by an implementation science framework. Given the focus on practice-ready accessible resources and products that could be readily integrated into practice, NIMH encourages the use of technology and other design features that make the tools scalable and robust against implementation drift, and a deployment-focused? approach that takes into account the perspectives of key stakeholders (e.g., service users, providers, administrators) and system-level factors, such as workforce capacity that influence potential integration of tools into clinical workflows. This FOA supports pilot effectiveness research to evaluate the feasibility, tolerability, acceptability, safety and preliminary indications of effectiveness of service-ready tools and technologies for suicide prevention and inform the design of definitive effectiveness trials. Support for fully-powered, definitive effectiveness studies focused on service-ready tools and technologies or suicide prevention is provided via the R01 in RFA-MH-21-110. Support for SBIR studies focused on service-ready tools and technologies or suicide prevention is provided via the R43/R44 in RFA-MH-21-112.

View more details on this opportunity.

___________________________________________________________

Department of Health and Human Services – National Institutes of Health – Understanding the Cellular and Molecular Mechanisms of Gastroparesis in Adults and Children (R01 Clinical Trial Not Allowed)

Letter of Intent Due Date: February 3, 2021

Proposal Due Date: March 3, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling: $250,000

Award Floor:

Funding Opportunity Number: RFA-DK-20-030 

Purpose: Since its establishment in 2006, the Gastroparesis Clinical Research Consortium (GpCRC), a multi-center coalition created and funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), has made major advances to our understanding of the pathophysiology of gastroparesis (Gp) and develop an effective treatment for patients with symptomatic gastroparesis. Through the establishment of the largest gastroparesis tissue repository, combined with detailed phenotypic data, the GpCRC is ideally suited to accelerate insights into the underlying cellular and molecular pathophysiology of the gastroparesis with the ultimate goal of developing therapeutic target(s). This RFA invites investigators from several disciplines, including basic and translational research in areas of neurosciences, immunology, microbiology and physiology, to contribute new insights into the cellular and molecular mechanisms of gastroparesis.

View more details on this opportunity.

___________________________________________________________

Department of Health and Human Services – National Institutes of Health – NIAMS Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)

Letter of Intent Due Date: 30 days prior to application due date

Proposal Due Date: March 4, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-036

Purpose: This Funding Opportunity Announcement (FOA) solicits cooperative agreement (U01) applications for implementation of investigator-initiated interventional clinical trials (all phases). Applications for clinical trials submitted to the NIAMS are normally expected to go through a two-part process, which begins with an R34 planning phase (Part 1) followed by an application for the U01 (Part 2). Investigators who have completed all necessary pre-trial planning and preparation through other means may apply for a NIAMS U01 without an awarded R34. The NIAMS expects trials to be hypothesis-driven and have the potential for high impact within the research mission of the NIAMS.

View more details on this opportunity.

___________________________________________________________

Department of Health and Human Services – National Institutes of Health – Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)

Proposal Due Date: March 4, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling: $250,000

Award Floor:

Funding Opportunity Number: PAR-21-053

Purpose: This Funding Opportunity Announcement (FOA) is to encourage Research Project Grant (R01) applications to pursue clinical observational (CO) studies to obtain data necessary for designing clinical studies for musculoskeletal, rheumatic, or skin diseases or conditions. A future clinical study may include a clinical trial or an observational study. Research data from observational studies supported by this FOA can enhance clinical study design by providing essential information about disease symptoms, stages, and timing of disease progression; comorbid conditions; availability of potential research participants; and outcomes that are important to patients. They also can facilitate efforts to develop and/or validate objective biomarkers or subjective outcome measures for use in a future clinical study. Applicants to this FOA are encouraged to propose studies that address significant obstacles or questions in the design of a clinical project, such as determining the appropriate primary or secondary outcome measures or identifying the stages of disease during which patients are most likely to respond to an intervention. Only observational studies will be supported through this FOA.

View more details on this opportunity.

___________________________________________________________

Department of Health and Human Services – National Institutes of Health – Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R21 Clinical Trial Required)

Proposal Due Date: March 4, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling: $200,000

Award Floor:

Funding Opportunity Number: PAR-21-045

Purpose: This Funding Opportunity Announcement (FOA) is designed to facilitate clinical trials that can be completed within a limited timeframe and budget. A broad range of types of exploratory studies may be submitted to this FOA. The trials must address research questions related to the mission and goals of the NIAMS and may evaluate interventions with drugs, biologics, devices, or surgical, dietary, behavioral or rehabilitation therapies.

View more details on this opportunity.

___________________________________________________________

Department of Health and Human Services – National Institutes of Health – Detection of HIV for Self-Testing (R61/R33 Clinical Trial Not Allowed)

Letter of Intent Due Date: 30 days prior to application due date

Proposal Due Date: March 17, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-070

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative, interdisciplinary early-stage research to inform the development of innovative rapid, sensitive, simple, and cost-effective diagnostic technologies that will enable HIV self-testing during the earliest phases of acute infection or during viral rebound.

View more details about this opportunity.

___________________________________________________________

Department of Health and Human Services – National Institutes of Health – Exploratory Centers for Interdisciplinary Research in Benign Urology (P20 Clinical Trial Optional)

Letter of Intent Due Date: February 18, 2021

Proposal Due Date: March 18, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-070

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to seek applications for Exploratory Centers for Interdisciplinary Research in Benign Urology (P20).  A major goal of this program is to build interdisciplinary research teams. The program seeks innovative, high-riskhigh-reward Research Projects that utilize integrative approaches to address questions relevant to benign genitourinary diseases or disorders bringing together investigators with complementary expertise. Studies involving human subjects or tissues and small, innovative, pilot and feasibility clinical studies are encouraged. The following expertise must be included in the proposed Research Project: 1) researchers new to the investigation of benign genitourinary diseases or disorders and 2) clinical urology expertise. Additional expertise may also be included, as needed. In addition to the scientific Research Project, each Exploratory Center must include an Administrative Core with an Educational Enrichment Program. As part of the NIDDK’s efforts to expand and enhance benign urology research and the base of urologic researchers, the Exploratory Centers Program will work in partnership with the George M. O’Brien Urology Cooperative Research Centers Program (U54) and the Multidisciplinary K12 Urologic Research (KURe and UroEpi) Career Development Programs.

View more details on this opportunity.